Amonafide: Difference between revisions

Browse history interactively ← Previous edit Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 05:07, 31 July 2011 editArcadian (talk \| contribs)163,050 edits removed Category:Chemotherapeutic agents; added Category:Experimental cancer drugs using HotCat ← Previous edit		Revision as of 01:28, 6 August 2011 edit undoCheMoBot (talk \| contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'DrugBank_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology\|erroNext edit →
Line 19:		Line 19:
	\| ATC_suffix =		\| ATC_suffix =
	\| PubChem = 50515		\| PubChem = 50515
			\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}
	\| DrugBank =		\| DrugBank =
	\| C=16\|H=17\|N=3\|O=3		\| C=16\|H=17\|N=3\|O=3

Revision as of 01:28, 6 August 2011

Pharmaceutical compound

Amonafide
Clinical data

ATC code	none
Identifiers
IUPAC name 5-amino-2--1H-benzoisoquinoline-1,3(2H)-dione
CAS Number	69408-81-7
PubChem CID	50515
ChemSpider	45804
UNII	1Q8D39N37L
ChEMBL	ChEMBL428676
CompTox Dashboard (EPA)	DTXSID30219562
Chemical and physical data
Formula	C₁₆H₁₇N₃O₃
Molar mass	283.325 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N
InChI InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3 Key:UPALIKSFLSVKIS-UHFFFAOYSA-N
(what is this?) (verify)

Amonafide (originally AS1413) (INN, trade name Quinamed) is a drug that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and DNA intercalators.

It is being developed as an anti-cancer therapy by Antisoma.

As of 2008, it is in Phase III clinical trials. eg In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).

References

http://www.genengnews.com/news/bnitem.aspx?name=78979622
http://clinicaltrials.gov/ct2/show/NCT00715637 "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study"

External links

Amonafide entry in the public domain NCI Dictionary of Cancer Terms
Clinical trials of amonafide at ClinicalTrials.gov

This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: